{"schema_version":"secwatch.filing_event.v1","accession":"0000010795-24-000078","form_type":"8-K","ticker":"BDX","cik":"0000010795","company_name":"BECTON DICKINSON & CO","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.598664+00:00","generated_at":"2026-05-30T03:15:12.981079+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BD Q4 FY2024 revenue $5.4B (+6.9%), adjusted EPS $3.81 (+11.4%); issues FY25 EPS guidance $14.25-$14.60","bullets":["Q4 revenue $5.4B, +6.9% as reported; GAAP EPS $1.45 (vs $0.53), adjusted EPS $3.81 (vs $3.42).","FY24 revenue $20.2B, +4.2%; adjusted EPS $13.14 (+7.6%); free cash flow $3.1B (+47.4%).","FY25 guidance: organic revenue growth 4.0-4.5%; adjusted diluted EPS $14.25-$14.60 (midpoint ~10% growth).","Completed acquisition of Edwards Lifesciences' Critical Care product group, expanding smart connected care portfolio."],"urls":{"canonical":"https://secwatch.observer/filing/0000010795-24-000078","json":"https://secwatch.observer/filing/0000010795-24-000078.json","markdown":"https://secwatch.observer/filing/0000010795-24-000078.md","text":"https://secwatch.observer/filing/0000010795-24-000078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/10795/000001079524000078/0000010795-24-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/10795/000001079524000078/bdx-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:15:12.981079+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}